← All trials
NCT06255834
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2024
- Primary completion
- Oct 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- Feb 13, 2024
- Last posted
- Apr 24, 2024
- Enrollment
- 66
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Immunophage Biotech Co., LtdLead sponsor
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.